Verrica Pharmaceuticals (VRCA) H.C. Wainwright 27th Annual Global Investment Conference summary

Business overview and recent progress

• Commercial-stage dermatology company with two late-stage assets targeting unmet needs in dermatology.

• CEO rejoined about a year ago to reframe commercial strategy and pipeline execution.

• YCANTH, a topical treatment for molluscum contagiosum, is FDA-approved for ages two and up and has shown sequential quarter-over-quarter growth in dispensed units.

• Partnership with Torii Pharmaceutical in Japan includes milestone payments and global development collaboration.

• IP protection for YCANTH extends through 2034–2041.

Pipeline and clinical development

• Global phase III program for YCANTH in common warts to launch by year-end, fully funded up to $40 million by Torii, with cost-sharing and milestone/royalty structure.

• Retains global rights to YCANTH outside Japan; first patient dosing expected by end of year.

• VP-315 for basal cell carcinoma completed phase II; phase III design underway, with data update planned at a major conference later this year.

Market opportunity and disease background

• Molluscum contagiosum affects 6 million in the US; common warts affect 22 million globally.

• Molluscum is highly contagious, persistent, and historically lacked robust treatments, leading to significant quality-of-life impacts.

• YCANTH is the only HCP-administered, FDA-approved treatment for molluscum, using cantharidin as the active ingredient.